Subsequently, the phase IIIb LUCY trial assessed the clinical effectiveness of Olaparib in patients with a gBRCA PVs affected by HER2-negative metastatic BC, in a setting designed to closely reflect real-world clinical practice [66]. The gene discussed is ERBB2; the disease is breast cancer.